Dabigatran Capsule 75 mg, 110 mg, and 150 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 75 mg, 110 mg, and 150 mg

Reference Brands: Pradaxa(EU & US)

Category: Blood Disorder

Dabigatran is a direct thrombin inhibitor that prevents clot formation by blocking thrombin's role in converting fibrinogen to fibrin. It effectively reduces stroke risk in atrial fibrillation, treats and prevents deep vein thrombosis and pulmonary embolism, with benefits including oral administration, predictable effects, and no routine blood monitoring.

Product Description: Dabigatran, marketed as Pradaxa, is approved in the US by the FDA and in the EU via EMA authorization. Regulatory approval requires a detailed dossier demonstrating safety, efficacy, manufacturing quality, and stability data. In the US, FDA approval involves a comprehensive submission, while the EU approval follows centralized or national procedures. Both regions emphasize pharmacovigilance and clinical data to ensure product compliance. For expert guidance on dossier preparation, regulatory strategies, and market entry, visit PharmaTradz. Ensuring thorough regulatory compliance is essential for successful approval, market access, and ensuring patient safety worldwide with dabigatran capsules.